Latest news with #YaronWerber
Business Insider
15-05-2025
- Business
- Business Insider
TD Cowen Remains a Buy on Nkarta (NKTX)
In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Nkarta (NKTX – Research Report). The company's shares closed yesterday at $1.87. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Werber is a 4-star analyst with an average return of 5.3% and a 46.68% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Stoke Therapeutics. Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $12.75. NKTX market cap is currently $143.3M and has a P/E ratio of -1.17.
Business Insider
13-05-2025
- Business
- Business Insider
TD Cowen Keeps Their Buy Rating on Jasper Therapeutics (JSPR)
In a report released yesterday, Yaron Werber from TD Cowen maintained a Buy rating on Jasper Therapeutics (JSPR – Research Report). The company's shares closed yesterday at $4.74. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Argenx Se, and Amgen. According to TipRanks, Werber has an average return of 5.2% and a 46.89% success rate on recommended stocks. Jasper Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $60.38. Based on Jasper Therapeutics' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.17 million and a net profit of $46.95 million. In comparison, last year the company earned a revenue of $2.05 million and had a GAAP net loss of $16.58 million
Reuters
03-04-2025
- Health
- Reuters
US FDA approves Amgen's Uplizna as first treatment for rare immune disorder
April 3 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of Amgen's (AMGN.O), opens new tab drug, Uplizna, to help reduce the risk of flares in patients with a rare immune system-related condition, the regulator said on Thursday. The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease (IgG4-RD), a rare condition in which an overactive immune system can lead to inflammation and scarring in various organs, including the pancreas, liver and kidneys. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Uplizna, given by infusion, is designed to bind to a protein located on the surface of B cells, the underlying inflammatory cause of IgG4-RD and other autoimmune conditions. "By removing or depleting these B cells throughout the body, both in the circulating blood and in the tissue, there's a chance for Uplizna to confer a real benefit," said Jay Bradner, Amgen's head of research and development. Around 20,000 people in the U.S. suffer from the condition, he said. The approval was based on data from a late-stage study in which Uplizna helped reduce the risk of flares by 87% compared to a placebo. "This would be a fairly compelling drug that is infrequent, fairly safe, and very effective," TD Cowen analyst Yaron Werber told Reuters ahead of the decision. Werber estimates Uplizna to generate global peak sales of $1.3 billion by 2030 for IgG4-RD alone. Uplizna, which was already approved for a rare, severe neuroinflammatory disease called neuromyelitis optica spectrum disorder, brought in sales of $379 million in 2024. Steroids — usually used to manage IgG4-RD — have many negative effects on patients, including mood changes, weight gain and osteoporosis, said Dr. Matthew Baker, associate division chief of immunology and rheumatology at Stanford University. "The goal with a treatment like this is to definitely minimize steroid exposure, and I think it certainly will do that," Dr. Baker said.
